The osteoporosis drug Aclasta has been linked to a number of serious side effects including low energy femur fractures (thigh bone fractures), osteomyelitis of the jaw, and osteonecrosis of the jaw (aka. Dead Jaw). These conditions are debilitating and can have a devastating impact on an individual’s quality of life. At Schmidt & Clark, LLP, we believe that drug companies who put profit before public safety should be held accountable for their negligence.
Aclasta Update 6/28/12: In a new web guide published by the FDA, the administration lays out new guidance for the use of bisphosphonates, tentatively recommending a three to five year time limit for the drugs, at least until more conclusive data becomes available. The five-year time limit was originally suggested in a September 2011 report issued by the FDA, which concluded that there appears to be no tangible benefit to extending bisphosphonate regimens beyond five years. Click here to learn more.
Aclasta Bone Fracture Update 5/24/12: In a study published this week by the Archives of Internal Medicine, Swiss researchers reached conclusions similar to those reached earlier this month by the U.S. Food & Drug Administration (FDA) – that taking osteoporosis drugs from the bisphosphonate class can increase the risk of atypical bone fractures. Taken cumulatively, the results of the study seem to suggest that the risk of fractures increased over time while the benefits of the drugs decreased. Click here to learn more.
Free Aclasta Case Evaluation: If you or a loved one has suffered from any of the side effects listed in this article after taking Aclasta, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
What’s the problem?
Aclasta (zoledronic acid) is a prescription medication used in the treatment of osteoporosis in post-menopausal women and Paget’s disease of the bone. It belongs to a group of drugs called bisphosphonates which inhibit the release of calcium from the bones. While most patients are given the drug for years at a time, numerous studies and adverse event reports suggest that long-term use of Aclasta may increase the risk of low-energy bone fractures, most commonly involving the thigh bone or femur.
In October 2010, the U.S. Food & Drug Administration (FDA) warned that bisphosphonates like Aclasta had been linked to two rare types of thigh fractures known as subtrochanteric and diaphyseal femur fractures. FDA said in its alert that these unusual femur fractures had been most often reported in patients taking bisphosphonates, and that these injuries may be related to the long-term use of these drugs. Then in February 2011, a study published in the Journal of the American Medical Association (JAMA) confirmed that long-term use of bisphosphonates like Aclasta increases the risk for atypical fractures in older women. Researchers concluded that among older women, treatment with a bisphosphonate for more than five years was associated with an increased risk of subtrochanteric or femoral shaft fractures.
Bisphosphonate Osteoporosis Drugs
In addition to Aclasta, bisphosphonate medications include:
If you are taking Aclasta
You should not take Aclasta if you have low blood calcium, cannot sit or stand for at least an hour at a time, have severe kidney disease, or are allergic to zoledronic acid. You should tell your healthcare provider if you experience painful swallowing, chest pain or severe heartburn, as these may be signs of serious upper digestive problems. Patients are strongly advised to weigh risks vs. benefits closely before taking Aclasta.
Do I have an Aclasta Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Aclasta lawsuits. We are handling individual litigation nationwide and currently accepting new bone fracture cases in all 50 states.